RS51091B - 2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti - Google Patents

2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti

Info

Publication number
RS51091B
RS51091B RSP-2009/0466A RSP20090466A RS51091B RS 51091 B RS51091 B RS 51091B RS P20090466 A RSP20090466 A RS P20090466A RS 51091 B RS51091 B RS 51091B
Authority
RS
Serbia
Prior art keywords
alkyl
phenyl
optionally substituted
halo
procedure
Prior art date
Application number
RSP-2009/0466A
Other languages
English (en)
Serbian (sr)
Inventor
Zhan Shi
Shaowu Chen
Paul E. Fleming
Jane F. Schmidt
John C. Reader
Neal D. Hone
Jefrey P. Ciavarri
Original Assignee
Millennium Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34749013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc. filed Critical Millennium Pharmaceuticals Inc.
Publication of RS51091B publication Critical patent/RS51091B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RSP-2009/0466A 2004-01-08 2005-01-10 2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti RS51091B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53489804P 2004-01-08 2004-01-08
PCT/US2005/000663 WO2005066139A2 (en) 2004-01-08 2005-01-10 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
RS51091B true RS51091B (sr) 2010-10-31

Family

ID=34749013

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0466A RS51091B (sr) 2004-01-08 2005-01-10 2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti

Country Status (18)

Country Link
US (2) US7732444B2 (enExample)
EP (2) EP2123647A1 (enExample)
JP (1) JP2007517895A (enExample)
AR (1) AR047185A1 (enExample)
AT (1) ATE437861T1 (enExample)
AU (1) AU2005204060A1 (enExample)
CA (1) CA2559888A1 (enExample)
CY (1) CY1109529T1 (enExample)
DE (1) DE602005015677D1 (enExample)
DK (1) DK1701944T3 (enExample)
ES (1) ES2330863T3 (enExample)
HR (1) HRP20090572T1 (enExample)
PL (1) PL1701944T3 (enExample)
PT (1) PT1701944E (enExample)
RS (1) RS51091B (enExample)
SI (1) SI1701944T1 (enExample)
TW (1) TW200533357A (enExample)
WO (1) WO2005066139A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
US20080318929A1 (en) * 2005-12-21 2008-12-25 Barbosa Antonio J M Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta
CA2644643C (en) * 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
DK2430921T3 (en) * 2007-04-03 2017-10-16 Du Pont SUBSTITUTED BENZEN FUNGICIDES
MX2010004740A (es) 2007-10-30 2010-05-27 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico.
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 ６員芳香環含有化合物
EP2169665B1 (en) 2008-09-25 2018-05-02 LG Electronics Inc. A method and an apparatus for processing a signal
WO2011083483A2 (en) * 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
CA2800936A1 (en) * 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
EP2739618B1 (en) 2011-08-04 2015-09-16 Array Biopharma, Inc. Quinazoline compounds as serine/threonine kinase inhibitors
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
SMT201800608T1 (it) 2012-04-24 2019-01-11 Vertex Pharma Inibitori di dna-pk
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
AU2014244555B2 (en) 2013-03-12 2018-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
HUE041877T2 (hu) 2013-10-17 2019-06-28 Vertex Pharma (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
US10485772B2 (en) 2014-08-25 2019-11-26 EpiAxis Therapeutics Pty Ltd. Compositions for modulating cancer stem cells and uses therefor
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
EP4444423A1 (en) 2021-12-06 2024-10-16 Helmholtz-Zentrum Dresden - Rossendorf e.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698697A (en) 1995-07-19 1997-12-16 Mitsubishi Chemical Corporation 2-cyanopiperazine and method of producing the same
AU1924699A (en) * 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE274510T1 (de) * 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
EE200100341A (et) * 1998-12-24 2002-12-16 Aventis Pharmaceuticals Products Inc. Asendatud (aminoiminometüül- või aminometüül)bensoheteroarüülühendid, nende kasutamine ja farmatseutiline kompositsioon
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
AR032130A1 (es) * 1999-08-13 2003-10-29 Vertex Pharma Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
AU1152702A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2441733A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1389206B1 (en) * 2001-04-13 2006-09-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
MXPA04004166A (es) * 2001-11-07 2004-07-08 Hoffmann La Roche Aminopirimidinas y piridinas.
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CA2489458A1 (en) * 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
EP1590334B1 (en) * 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7459460B2 (en) * 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
ES2505090T3 (es) * 2004-05-07 2014-10-09 Amgen Inc. Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer
BRPI0511978A (pt) * 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
JP2008519034A (ja) * 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
MX2007007032A (es) * 2004-12-17 2007-07-04 Amgen Inc Compuestos de aminopirimidina y metodos de uso.
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DE102005034821A1 (de) * 2005-07-26 2007-02-08 Fleissner Gmbh Voluminöse Faserlaminate und ihre Herstellung
TWM293131U (en) * 2006-01-10 2006-07-01 Shuen Tai Prec Entpr Co Ltd Handheld power hammer

Also Published As

Publication number Publication date
US8268822B2 (en) 2012-09-18
AR047185A1 (es) 2006-01-11
WO2005066139A2 (en) 2005-07-21
DE602005015677D1 (de) 2009-09-10
EP1701944A2 (en) 2006-09-20
US20060040968A1 (en) 2006-02-23
US7732444B2 (en) 2010-06-08
PT1701944E (pt) 2009-11-03
ES2330863T3 (es) 2009-12-16
EP2123647A1 (en) 2009-11-25
ATE437861T1 (de) 2009-08-15
WO2005066139A3 (en) 2005-10-13
SI1701944T1 (sl) 2010-03-31
PL1701944T3 (pl) 2010-01-29
CY1109529T1 (el) 2014-08-13
US20110071134A1 (en) 2011-03-24
TW200533357A (en) 2005-10-16
HRP20090572T1 (hr) 2010-01-31
AU2005204060A1 (en) 2005-07-21
EP1701944B1 (en) 2009-07-29
DK1701944T3 (da) 2009-11-09
CA2559888A1 (en) 2005-07-21
JP2007517895A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
US8268822B2 (en) 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
CN104540809B (zh) 成纤维细胞生长因子受体的抑制剂
TWI816809B (zh) 黑皮質素亞型-2受體(mc2r)拮抗劑及其用途
AU2014214254B2 (en) Macrocyclic Pyridazinone derivatives
US20100113445A1 (en) Chemical Compounds
RU2671864C2 (ru) N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств
CA2477505A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
CN101641346B (zh) 作为mglur2拮抗剂的吡啶和嘧啶衍生物
CA2469316A1 (en) Pyrimidine-based compounds useful as gsk-3 inhibitors
CA2683619A1 (en) Pharmaceutical compounds
BRPI0709007A2 (pt) inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos
AU2006332694A1 (en) Substituted bis-amide metalloprotease inhibitors
TW200840580A (en) Heterocyclic aspartyl protease inhibitors
AU2005295788A1 (en) N-benzenesulfonyl substituted anilino-pyrimidine analogs
AU2013331626A1 (en) Therapeutic compounds and compositions
KR20180015261A (ko) 신규한 아미노산 유도체, 이의 제조방법, 및 이를 함유한 약제 조성물
MXPA06000051A (es) Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje.
RS55793B1 (sr) 6-alkinil piridini kao smac mimetici
JP2019515932A (ja) チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物
US7329678B2 (en) Chemical compounds
CN110305125A (zh) 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
AU2006237365A1 (en) 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
EP1966163A1 (en) Pyrimidine derivatives useful as inhibitors of pkc-theta
CN112341431A (zh) 作为fgfr4抑制剂的杂环化合物
CN115551845B (zh) Phd抑制剂化合物、组合物和用途